Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients

2008137 citationsJournal Article

Authors

Jean‐François Delfraissy · Assistance Publique – Hôpitaux de Paris

Philippe Flandre · Sorbonne Université

Constance Delaugerre · Assistance Publique – Hôpitaux de Paris

Jade Ghosn · Assistance Publique – Hôpitaux de Paris

Andrzej Horban · Medical University of Warsaw

Pierre‐Marie Girard · Assistance Publique – Hôpitaux de Paris

Michael Norton

Abstract

Our results suggest that lopinavir/ritonavir monotherapy demonstrates lower rates of virological suppression when compared with lopinavir/ritonavir triple therapy and therefore should not be considered as a preferred treatment option for widespread use in antiretroviral-naive patients.

Topics & Keywords

HIV/AIDS drug development and treatment HIV Research and Treatment HIV/AIDS Research and Interventions

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: AIDS

Volume 22, Issue 3, pp. 385-393

DOI: 10.1097/qad.0b013e3282f3f16d

Field-Weighted Citation Impact: 12.98